Matthew Lee, DO
Medical Oncology · San Mateo, CANPI 1326589581
Payments from drug & device makers
Across 46 payments — averaging $49.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$398
- Lilly USA, LLC$374
- Johnson & Johnson$238
- Seagen Inc.$183
- AstraZeneca$169
- Amgen$145
- plus $793 from 14 others
What the payments were for
- Food & beverage$1,70074%
- Education$60026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 9 | $398 |
| Lilly USA, LLC | 5 | $374 |
| Johnson & Johnson | 2 | $238 |
| Seagen Inc. | 3 | $183 |
| AstraZeneca(2 entities) | 4 | $169 |
| Amgen | 3 | $145 |
| Eisai Inc. | 2 | $139 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $103 |
| Astellas Pharma US Inc | 1 | $95 |
| Novartis | 3 | $73 |
| Merck | 2 | $54 |
| Pharmacosmos Therapeutics Inc. | 2 | $45 |
| AbbVie | 1 | $41 |
| Pfizer | 1 | $24 |
| Sobi, Inc | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Legend Biotech USA Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,299 in reported general payments places this provider in the 25th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 12 | $252 |
| Dexamethasone | 16 | $128 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in San Mateo
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
- Sandhya SrinivasStanford$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.